CEO Adrian Rawcliffe was paid $2,109,075 in fiscal year 2024, ↓ down 24.0% from fiscal year 2023, the 25th percentile of its disclosed peer group (SEC filing 0001104659-25-039042 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,109,075 ↓ Adrian Rawcliffe total, FY2024 | 25th CEO pay percentile vs peers | — CEO-to-median pay ratio | 97.05% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Adrian Rawcliffe | $676,000 | — | $0 | $1,065,820 | $324,480 | $0 | $42,775 | $2,109,075 |
| Chief Executive Officer and Director | ||||||||
| Cintia Piccina | 363,251 | — | 0 | 1,235,787 | 131,100 | 0 | 16,158 | 1,746,296 |
| Chief Commercial Officer | ||||||||
| William Bertrand | 486,906 | — | 0 | 355,272 | 175,286 | 0 | 40,905 | 1,058,369 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Adrian Rawcliffe | $2,109,075 | $2,774,041 | — | ↓ −664,966 |
| Cintia Piccina | 1,746,296 | 992,342 | — | ↑ +753,954 |
| William Bertrand | 1,058,369 | 1,215,100 | — | ↓ −156,731 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Adaptimmune Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ADAP reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ADAP in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ADAP in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2024 total |
|---|---|---|
| Adrian Rawcliffe | CEO | $2,109,075 |
| Cintia Piccina | CCO | $1,746,296 |
| William Bertrand | COO | $1,058,369 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Ali Behbahani | Independent Director | $152,086 |
| Andrew Allen | Independent Director | $140,123 |
| David M. Mott | Chair of the Board | $204,195 |
| Garry Menzel | Independent Director | $144,659 |
| John Furey | Independent Director | $142,623 |
| Kristen Hege | Independent Director | $141,524 |
| Lawrence M. Alleva | Independent Director | $156,566 |
| Priti Hegde | Independent Director | $173,886 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Greater-than-10% holder | 2025-07-28 | D | 33,931,740 | $0 | $3,817,321 | Common | Form 4 ↗ |
| EcoR1 Capital, LLC | Greater-than-10% holder | 2025-07-29 | D | 2,687,460 | 0 | 271,971 | Common | Form 4 ↗ |
| EcoR1 Capital, LLC | Greater-than-10% holder | 2025-07-30 | D | 27,433,338 | 0 | 2,800,944 | Common | Form 4 ↗ |
| Ali Behbahani | Director | 2025-08-15 | D | 4,828,206 | 0 | 53,110 | Common, indirect | Form 4 ↗ |
| Ali Behbahani | Director | 2025-08-18 | D | 14,671,794 | 0 | 176,062 | Common, indirect | Form 4 ↗ |
| William Bertrand | Chief Operating Officer | 2025-08-28 | D | 207,000 | 0 | 2,091 | Common | Form 4 ↗ |
| Gavin Wood | Chief Financial Officer | 2025-09-02 | D | 96,000 | 0 | 950 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| William Bertrand | Option | 381,174 | 0.55 | — |
| William Bertrand | RSU | 235,692 | — | 0 |
| Cintia Piccina | RSU | 1,125,648 | — | 0 |
| Adrian Rawcliffe | Option | 67,925 | 0.95 | — |
| William Bertrand | RSU | 674,178 | — | 732,894 |
| Adrian Rawcliffe | RSU | 182,040 | — | 0 |
| Adrian Rawcliffe | RSU | 1,696,272 | — | 0 |
| William Bertrand | RSU | 565,416 | — | 0 |
| Adrian Rawcliffe | RSU | 2,247,366 | — | 2,442,858 |
| Adrian Rawcliffe | RSU | 523,740 | — | 0 |
| Adrian Rawcliffe | Option | 1,270,338 | 0.55 | — |
| Adrian Rawcliffe | RSU | 1,348,704 | — | 0 |
| Adrian Rawcliffe | RSU | 7,633,296 | — | 0 |
| William Bertrand | RSU | 60,678 | — | 0 |
| William Bertrand | Option | 22,642 | 0.95 | — |
| Cintia Piccina | RSU | 753,888 | — | 0 |
| Cintia Piccina | RSU | 2,531,661 | — | 2,557,203 |
| Adrian Rawcliffe | RSU | 628,872 | — | 0 |
| William Bertrand | RSU | 157,128 | — | 0 |
| William Bertrand | RSU | 2,544,432 | — | 0 |
Our philosophy in setting compensation policies for executive officers has two objectives: (1) to attract and retain a highly skilled team of executives and (2) to align our executives' interests with those of our shareholders by rewarding short-term and long-term performance.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-29 | 788,416,380 | 23,994,566 | 6,559,240 | 97.05% | Passed |
| 2024 | 2024-05-14 | 986,885,460 | 52,365,878 | 1,074,150 | 94.96% | Passed |
| 2022 | 2022-05-25 | 676,250,162 | 12,745,380 | 23,730,706 | 98.15% | Passed |
| 2021 | 2021-05-14 | 661,563,956 | 2,652,246 | 550,362 | 99.6% | Passed |
| 2020 | 2020-05-29 | 624,514,856 | 1,969,536 | 4,716,174 | 99.69% | Passed |
| 2019 | 2019-05-02 | 494,043,120 | 2,346,090 | 4,376,364 | 99.53% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-05-29 | 97.05%a |
| 2024 | 2024-05-14 | 94.96%b |
| 2022 | 2022-05-25 | 98.15%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David M. MottIndependent · Board Chair · Remuneration (Chair) · Corporate Governance and Nominating (Chair) · Not standing for re-election | $0 | $0 | $204,195 | — | $0 | $204,195 |
| Priti HegdeIndependent · Corporate Governance and Nominating · Research and Development · Not standing for re-election | 26,250 | 0 | 147,636 | — | 0 | 173,886 |
| Lawrence M. AllevaIndependent · Audit (Chair) · Not standing for re-election | 0 | 0 | 156,566 | — | 0 | 156,566 |
| Ali BehbahaniIndependent · Corporate Governance and Nominating · Research and Development | 0 | 0 | 152,086 | — | 0 | 152,086 |
| Garry MenzelIndependent · Audit · Not standing for re-election | 0 | 0 | 144,659 | — | 0 | 144,659 |
| John FureyIndependent · Audit · Remuneration | 57,500 | 0 | 85,123 | — | 0 | 142,623 |
| Kristen HegeIndependent · Research and Development (Chair) · Not standing for re-election | 47,500 | 0 | 94,024 | — | 0 | 141,524 |
| Andrew AllenIndependent · Remuneration · Research and Development · Not standing for re-election | 55,000 | 0 | 85,123 | — | 0 | 140,123 |
| Adrian RawcliffeEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $186,250 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $186,250 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Adaptimmune Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Adaptimmune Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunocore Holdings plc | 2025 | Bahija Jallal | $765,000 | $2,819,992 | $6,579,990 | $688,500 | $10,885,268 |
| 2 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 3 | Bicycle Therapeutics plc | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 4 | Precigen, Inc. | 2025 | Helen Sabzevari | 1,000,000 | 2,215,000 | 1,069,200 | 1,049,997 | 5,354,329 |
| 5 | Lyell Immunopharma, Inc. | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 6 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 7 | bluebird bio, Inc. | 2023 | Andrew Obenshain | 681,657 | 863,590 | 1,142,440 | 348,024 | 3,049,181 |
| 8 | Nkarta, Inc. | 2025 | Paul Hastings | 674,384 | 236,250 | 1,711,957 | 344,947 | 2,978,038 |
| 9 | Sana Biotechnology, Inc. | 2025 | Steven Harr | 696,140 | 425,001 | 1,327,500 | 450,369 | 2,903,010 |
| 10 | Coherus BioSciences, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 11 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 12 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 13 | Adaptimmune Therapeutics | 2024 | Adrian Rawcliffe | 676,000 | 0 | 1,065,820 | 324,480 | 2,109,075 |
| 14 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 15 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 16 | Inovio Pharmaceuticals, Inc. | 2025 | Jacqueline Shea | 728,000 | 346,101 | 351,955 | 144,144 | 1,587,155 |
| 17 | Century Therapeutics, Inc. | 2025 | Gregory Russotti | 559,650 | 71,120 | 51,240 | 226,658 | 912,320 |
| — | Autolus Therapeutics plc | — | — | — | — | — | — | not in coverage universe |
| — | Sangamo Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Instil Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Adaptimmune Therapeutics | 80% | Options 75 · RSU 25 | not disclosed | Pearl Meyer |
| Autolus Therapeutics plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Bicycle Therapeutics plc | 97% | not disclosed | not disclosed | not disclosed |
| bluebird bio, Inc. | 85% | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Aon plc (Human Capital Solutions practice) |
| Caribou Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Century Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Coherus BioSciences, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Immunocore Holdings plc | 120% | Options 70 · RSU 30 | not disclosed | Aon |
| Inovio Pharmaceuticals, Inc. | 33% | not disclosed | Yes — Relative TSR | Aon (Human Capital Solutions practice) |
| Instil Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Lyell Immunopharma, Inc. | 100% | not disclosed | No | Alpine |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Nkarta, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Poseida Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Precigen, Inc. | 140% | not disclosed | not disclosed | Aon |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Sana Biotechnology, Inc. | 107.5% | not disclosed | not disclosed | Aon plc (Human Capital Solutions practice) |
| Sangamo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Adrian Rawcliffe | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “2024 Summary Compensation Table”. As printed: 2,109,075. Filing ↗machine: r1 · c41 · span 814415–814424 |
| 2 | Section 01, Cintia Piccina | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “2024 Summary Compensation Table”. As printed: 1,746,296. Filing ↗machine: r5 · c41 · span 831352–831361 |
| 3 | Section 01, William Bertrand | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “2024 Summary Compensation Table”. As printed: 1,058,369. Filing ↗machine: r3 · c41 · span 822768–822777 |
| 4 | Section 08, David M. Mott | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 204,195. Filing ↗machine: t10 · r1 · c11 · span 547906–547913 |
| 5 | Section 08, Priti Hegde | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 173,886. Filing ↗machine: t10 · r6 · c17 · span 559303–559310 |
| 6 | Section 08, Lawrence M. Alleva | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 156,566. Filing ↗machine: t10 · r3 · c11 · span 552274–552281 |
| 7 | Section 08, Ali Behbahani | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 152,086. Filing ↗machine: t10 · r4 · c11 · span 554445–554452 |
| 8 | Section 08, Garry Menzel | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 144,659. Filing ↗machine: t10 · r8 · c11 · span 563167–563174 |
| 9 | Section 08, John Furey | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 142,623. Filing ↗machine: t10 · r5 · c17 · span 557135–557142 |
| 10 | Section 08, Kristen Hege | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 141,524. Filing ↗machine: t10 · r7 · c17 · span 561496–561503 |
| 11 | Section 08, Andrew Allen | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 140,123. Filing ↗machine: t10 · r2 · c17 · span 550575–550582 |
| 12 | Section 08, Adrian Rawcliffe | DEF 14A | 2025-04-25 | 0001104659-25-039042 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 02, EcoR1 Capital, LLC 2025-07-28 | Form 4 | 2025-07-30 | 0000935836-25-000476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 14 | Section 02, EcoR1 Capital, LLC 2025-07-29 | Form 4 | 2025-07-30 | 0000935836-25-000476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, EcoR1 Capital, LLC 2025-07-30 | Form 4 | 2025-07-30 | 0000935836-25-000476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Ali Behbahani 2025-08-15 | Form 4 | 2025-08-19 | 0000950170-25-110254 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Ali Behbahani 2025-08-18 | Form 4 | 2025-08-19 | 0000950170-25-110254 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, William Bertrand 2025-08-28 | Form 4 | 2025-08-29 | 0001104659-25-085820 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Gavin Wood 2025-09-02 | Form 4 | 2025-09-03 | 0001104659-25-087085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 06, 2025 vote | Form 8-K | 2025-05-29 | 0001104659-25-054232 | Item 5.07 · say-on-pay result. As reported: 97.05% (votes for as printed: 788,416,380). Filing ↗ |
| 21 | Section 06, 2024 vote | Form 8-K | 2024-05-14 | 0001104659-24-060884 | Item 5.07 · say-on-pay result. As reported: 94.96% (votes for as printed: 986,885,460). Filing ↗ |
| 22 | Section 06, 2022 vote | Form 8-K | 2022-05-25 | 0001104659-22-064428 | Item 5.07 · say-on-pay result. As reported: 98.15%. Filing ↗ |
| 23 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 24 | Section 09b board cost (computed) | Computed | — | — | Cash 186,250 + equity 0 + all other 0 = 186,250, summed across the director compensation table rows.machine: formula: Σ = 186,250 |
| 25 | Immunocore Holdings plc, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001140361-26-015122 | CEO total compensation as printed in Immunocore Holdings plc's own proxy. As printed: 10,885,268. Filing ↗machine: r2 · c24 · span 670285–670295 |
| 26 | Dynavax Technologies Corporation, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. Filing ↗ |
| 27 | Bicycle Therapeutics plc, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle Therapeutics plc's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 28 | Precigen, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018214 | CEO total compensation as printed in Precigen, Inc.'s own proxy. As printed: 5,354,329. Filing ↗machine: r2 · c24 · span 721439–721448 |
| 29 | Lyell Immunopharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016686 | CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172 |
| 30 | Poseida Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2024-04-25 | 0000950170-24-048291 | CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164 |
| 31 | bluebird bio, Inc., Section 10b CEO total | DEF 14A | 2024-09-26 | 0001293971-24-000049 | CEO total compensation as printed in bluebird bio, Inc.'s own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796 |
| 32 | Nkarta, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016403 | CEO total compensation as printed in Nkarta, Inc.'s own proxy. As printed: 2,978,038. Filing ↗machine: r2 · c27 · span 344226–344235 |
| 33 | Sana Biotechnology, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174883 | CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. Filing ↗machine: t69 · r3 · c27 · span 235773–235782 |
| 34 | Coherus BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045251 | CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. Filing ↗ |
| 35 | Fate Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177094 | CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560 |
| 36 | Precision BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013757 | CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 37 | Adaptimmune Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-04-25 | 0001104659-25-039042 | CEO total compensation as printed in Adaptimmune Therapeutics's own proxy. As printed: 2,109,075. Filing ↗machine: r1 · c41 · span 814415–814424 |
| 38 | MacroGenics, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001125345-26-000021 | CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198 |
| 39 | Caribou Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-05-01 | 0001619856-26-000028 | CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. Filing ↗machine: r2 · c39 · span 191689–191698 |
| 40 | Inovio Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001055726-26-000011 | CEO total compensation as printed in Inovio Pharmaceuticals, Inc.'s own proxy. As printed: 1,587,155. Filing ↗machine: r4 · c24 · span 548358–548367 |
| 41 | Century Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001104659-26-049489 | CEO total compensation as printed in Century Therapeutics, Inc.'s own proxy. As printed: 912,320. Filing ↗machine: r3 · c26 · span 521444–521451 |
| 42 | Section 10a, Bicycle Therapeutics plc reciprocity | DEF 14A | — | 0001558370-25-005258 | Bicycle Therapeutics plc's most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
| 43 | Section 10a, Coherus BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-045251 | Coherus BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
| 44 | Section 10a, Dynavax Technologies Corporation reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies Corporation's most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
| 45 | Section 10a, Immunocore Holdings plc reciprocity | DEF 14A | — | 0001140361-26-015122 | Immunocore Holdings plc's most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
| 46 | Section 10a, Inovio Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001055726-24-000014 | Inovio Pharmaceuticals, Inc. names Adaptimmune Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 47 | Section 10a, MacroGenics, Inc. reciprocity | DEF 14A | — | 0001125345-26-000021 | MacroGenics, Inc. names Adaptimmune Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 48 | Section 10a, Precigen, Inc. reciprocity | DEF 14A | — | 0001140361-26-018214 | Precigen, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
| 49 | Section 10a, Precision BioSciences, Inc. reciprocity | DEF 14A | — | 0001140361-26-013757 | Precision BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
| 50 | Section 10a, Lyell Immunopharma, Inc. reciprocity | DEF 14A | — | 0001140361-24-021008 | Lyell Immunopharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptimmune Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.